Category: General Biotechnology

Exubera: The road to hell is paved with good intentions

I’ve been waiting to write up the Exubera story for the next edition of Building Biotechnology, and the story just keeps getting better. Exubera is was Pfizer’s innovative answer to the diabetes drug market. The market is so saturated with competitive products, that the only way to capture significant market share is to innovate. Either […]

Biotech for Turkey

I’ll be speaking at the Biotech for Turkey conference in Istanbul on November 7th. This conference, convened by Bosfor Biotech Partners, will cover global biotechnology strategies and developments in Turkey. For more details, contact Bosfor Biotech at the URL above or browse the conference schedule: Biotech for Turkey

Journal of Commercial Biotechnology

A new issue of the Journal of Commercial Biotechnology has just been posted. Drop me a line if you would like to make a submission. Volume 13, Issue 4 Editorial Editorial PDF Neil Henderson Articles Is ‘evergreening’ a cause for concern? A legal perspective PDF Scott Parker, Kevin Mooney Exploiting the business opportunities in biotech […]

Pharma to support the international space station?

Wired has an article on the potential for the pharmaceutical industry to support the international space station, using the microgravity environment to grow better quality crystals than can be grown on earth, in less time. Protein crystals can be used to improve drug discovery, but the distance from crystal to drug is very long. Much […]

Drug Patent Expirations in October 2007

Courtesy of Drug Patent Expirations in October 2007*Drugs may be covered by more than one patent Tradename Applicant Generic Name Patent Number Patent Expiration CLARINEX Schering desloratadine 4,659,716 OCT 01,2007 CLARINEX Schering Plough desloratadine 4,659,716 OCT 01,2007 CLARINEX D 24 HOUR Schering desloratadine; pseudoephedrine sulfate 4,659,716 OCT 01,2007 CLARINEX-D 12 HOUR Schering desloratadine; pseudoephedrine […]

Manufacturing is dead. Long live manufacturing!

On the same day that AstraZeneca has announced that it intents to completely outsource all of its drug manufacturing, citing the prevalence of external parties who can do it better and cheaper, Sanofi has announced plans toIf you understand the rules and strategies of <a href=”http;//” mce_href=”http;//”>free blackajck online</a> it won’t be difficult for you. […]

Upcoming events

I’ll be attending the Mid-Atlantic Bio in Bethesda in late October. On November 8th I’ll be in Turkey speaking at the Biotechnology for Turkey Conference. I’ll be in Toronto in late November, speaking in the AstraZeneca speaker series at the University of Toronto. If you’re interested in more details or want to meet up, drop […]

Building Biotechnology on Facebook

With the start of a new school year, a new cohort of students are entering biotechnology programs. In order to facilitate those who are using my book, Building Biotechnology, I have set up a networking and information group on facebook. I’m always interested in tracking the outcomes of students in biotechnology programs. If you’re a […]

Drug Patent Expirations in September 2007

Courtesy of Drug Patent Expirations in September 2007*Drugs may be covered by more than one patent Tradename Applicant Generic Name Patent Number Patent Expiration BETAXON Alcon levobetaxolol hydrochloride 4,911,920 SEP 27,2007 BETOPTIC S Alcon betaxolol hydrochloride 4,911,920 SEP 27,2007 CARDIOLITE Bristol Myers Squibb technetium tc-99m sestamibi kit 4,885,100 SEP 11,2007 COGNEX Sciele Pharma Inc […]

Amgen’s patents protect Epogen. Again.

Amgen’s got a record of savvy patenting to protect their blockbusters, and they’ve just done it again. A U.S. Federal District Court in Boston has ruled that Roche’s pegylated-erythropoietin infringes one of Amgen’s patents. I’m eager to hear the backstory on this one. Amgen previously prevented Transkaryotic (now owned by Shire) from using a completely […]

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: